Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
Sakti Chakrabarti, Heidi D. Finnes, Amit Mahipal
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 85-98
Closed Access | Times Cited: 15

Showing 15 citing articles:

Design and Synthesis of 1,3,4-Oxadiazole–Quinazolinone Hybrids, Evaluation of Their Anticancer and Antimicrobial Activities, and Docking Studies
N. Suryanarayana, Ch. Sridhar, Himabindu Gandham
Russian Journal of Organic Chemistry (2025) Vol. 61, Iss. 1, pp. 92-104
Closed Access
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers
Ruyin Chen, Dandan Zheng, Qiong Li, et al.
Cancer Letters (2022) Vol. 546, pp. 215853-215853
Closed Access | Times Cited: 21
Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
Ying Zhang, Ran Li, Yongchao Liang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A
Lloyd Wei Tat Tang, Jiaxin Fu, Siew Kwan Koh, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 7, pp. 931-941
Open Access | Times Cited: 12
Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
Lloyd Wei Tat Tang, Guoyi Wu, Eric Chun Yong Chan
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 382, Iss. 2, pp. 123-134
Open Access | Times Cited: 10
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
Michael H. Storandt, Zhaohui Jin, Amit Mahipal
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 12, pp. 1265-1274
Closed Access | Times Cited: 9
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy
Zachary J. Brown, Samantha M. Ruff, Timothy M. Pawlik
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 257-264
Closed Access | Times Cited: 5
Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation
Lloyd Wei Tat Tang, Eric Chun Yong Chan
Biochemical Pharmacology (2022) Vol. 206, pp. 115336-115336
Closed Access | Times Cited: 8
Suppression of mTOR Expression by siRNA Leads to Cell Cycle Arrest and Apoptosis Induction in MDA-MB-231 Breast Cancer Cells
Roja Sahu, Shivesh Jha, Shakti Prasad Pattanayak
Current Gene Therapy (2023) Vol. 23, Iss. 3, pp. 228-242
Closed Access | Times Cited: 4
pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells
Ju-Il Yang, Hye Lim Lee, Je-Jung Yun, et al.
Materials (2022) Vol. 15, Iss. 11, pp. 3795-3795
Open Access | Times Cited: 6
A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
Lei Zhang, Hao Zheng, Linyu Xu, et al.
Diagnostics (2023) Vol. 13, Iss. 12, pp. 2088-2088
Open Access | Times Cited: 1
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions
Daniel Neureiter, Peter Ellinghaus, Matthias Ocker
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 17, pp. 1833-1837
Open Access | Times Cited: 1
Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers
Mohamedraed Elshami, John B. Ammori, Jeffrey M. Hardacre, et al.
Journal of Surgical Research (2023) Vol. 295, pp. 705-716
Closed Access | Times Cited: 1
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma
Sri Harsha Tella, Amit Mahipal
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 17, pp. 1879-1885
Closed Access | Times Cited: 2
Targeted therapy
Surya K. De
Elsevier eBooks (2023), pp. 205-411
Closed Access
Infigratinib, a selective FGFR1‐3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses
Zachary Michel, Sarah F. Aitken, Omar D. Glover, et al.
Developmental Dynamics (2023) Vol. 252, Iss. 12, pp. 1428-1448
Open Access
Page 1

Scroll to top